Microsystem enabled single cell monoclonal antibody cloning for antibody immunotherapy of HIV infection (features)

Monoclonal antibodies (mAbs) have well established their valuable roles as therapeutic proteins. Second generation of mAbs as therapeutical products for immunotherapy of HIV infection has made significant progress in recent studies. A recent small phase 1 clinical trial has demonstrated that monoclonal antibodies could be safe and effective in reducing HIV-1 viraemia in human. This study also suggested that passive transfer of mAbs will provide a potential alternative strategy for HIV-1 prevention, therapy, and cure. Single cell mAb cloning using either hydridoma technique or fluorescent activated cell sorting (FACS) is less efficient. Microsystem will enable a more efficient approach for single cell MAb cloning of bNAbs for HIV infection.